10-KPeriod: FY2007

IDEXX LABORATORIES INC /DE Annual Report, Year Ended Dec 31, 2007

Filed February 27, 2008For Securities:IDXX

Summary

IDEXX Laboratories, Inc. (IDXX) reported robust financial performance for the fiscal year ending December 31, 2007. The company demonstrated significant revenue growth, driven by strong performance across its key segments, particularly the Companion Animal Group (CAG). Total revenue increased to $922.6 million, a substantial rise from $739.1 million in 2006, indicating successful market penetration and product acceptance. The company's strategic acquisitions also played a crucial role in its expansion, contributing to a notable increase in goodwill and intangible assets on the balance sheet. Despite increased investment in property and equipment and acquisitions, IDEXX maintained healthy profitability and cash flow generation. The company's financial position appears solid, with a growing equity base and effective management of its debt facilities. Investors can look to IDEXX's continued focus on innovation and market expansion as key drivers for future growth.

Key Highlights

  • 1Revenue increased by approximately 25% year-over-year, reaching $922.6 million in 2007.
  • 2Gross profit grew to $463.5 million, up from $379.5 million in 2006, demonstrating improved operational efficiency.
  • 3Net income remained strong at $94.0 million, showing a slight increase from $93.7 million in 2006, with diluted EPS at $1.46.
  • 4Goodwill and other intangible assets significantly increased to $236.4 million due to strategic acquisitions.
  • 5Total assets grew to $702.2 million from $559.6 million, reflecting expansion and investments.
  • 6The company repurchased treasury stock valued at $118.8 million in 2007, underscoring its commitment to shareholder value.
  • 7Total stockholders' equity increased to $438.3 million, indicating a strengthening balance sheet.

Frequently Asked Questions

In 2007, IDEXX Laboratories primarily operated through three business segments: products and services for the veterinary market (Companion Animal Group - CAG), water quality products (Water), and products for production animal health (Production Animal Segment - PAS). They also had smaller segments for dairy quality (Dairy) and human medical diagnostics (OPTI Medical).

IDEXX Laboratories experienced significant revenue growth, with total revenue reaching $922.6 million in 2007, an increase from $739.1 million in 2006, representing a growth of approximately 25%. This growth was primarily driven by strong performance in the Companion Animal Group (CAG) and strategic acquisitions.

The substantial increase in goodwill and other intangible assets to $236.4 million in 2007 is a direct result of IDEXX's active acquisition strategy. This indicates the company has been investing in expanding its business through mergers and acquisitions, aiming to enhance its market position and product offerings.

IDEXX entered into a significant unsecured revolving credit facility in January 2007, which was later amended and increased. At the end of 2007, the company had $72.2 million outstanding under this facility. This indicates a strategic use of debt financing for general corporate purposes, including stock repurchases and acquisitions, while maintaining covenants that suggest a healthy debt-to-EBITDA ratio.